Real-World Data Study Shows Letrozole and Palbociclib Combo Effective for Black or Hispanic Breast Cancer Patients

January 19, 2023

Although frontline letrozole and palbociclib combination therapy did not improve survival for patients with estrogen receptor-positive, HER2-negative, advanced breast cancer in clinical trials, Black and/or Hispanic patients saw an increase in progression-free survival and overall survival. Dr. Adam Brufsky discussed the study in a talk at the San Antonio Breast Cancer Symposium.

According to , “There’s always going to be confounding and bias, but we use things like inverse probability treatment waiting, and propensity score matching to try to match them as closely as we could. When we did that, we found not only a progression-free survival benefit that was very similar to that seen in PALOMA-2, but there was an overall survival benefit that was totally significant. So even though the randomized trial didn’t show any benefit in terms of overall survival with Palbociclib, the real data did.”

To read more, click here.

(Source: Targeted Oncology, January 18th, 2023)

Share This Story!